We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Electronic Genome Mapping Reveals Structural Abnormalities in Hematologic Malignancies

By LabMedica International staff writers
Posted on 22 Sep 2026

Cytogenomic profiling is fundamental to characterizing hematologic malignancies, where detection of structural variants and copy number variants guides high‑resolution analysis. More...

Standard cytogenetic testing and optical genome mapping are used to identify these abnormalities, but complex cases and smaller variants can be difficult to resolve comprehensively. Electronic approaches that analyze ultra‑long DNA may enable more detailed interrogation of genome structure. A new study shows how an electronic genome mapping platform performed against established methods in previously characterized leukemia samples.

Augusta University (Augusta, Georgia) researchers evaluated the Nabsys OhmX Platform implementing Electronic Genome Mapping (EGM) for cytogenomic analysis of hematologic malignancies. In a proof‑of‑principle design, the team examined previously characterized bone marrow aspirate specimens and compared EGM findings with karyotyping, fluorescence in situ hybridization (FISH), and optical genome mapping (OGM).

The OhmX Platform uses EGM to analyze ultra‑long DNA molecules electronically. Unlike traditional genome mapping systems that rely on lasers, cameras, and complex optics, EGM integrates electronic detection, nanofluidics, and computational biology in a compact system designed to deliver high‑resolution information about genome structure. According to Nabsys, the platform is research‑use‑only and is commercially available to laboratories worldwide.

The study included four acute myeloid leukemia (AML) samples and one chronic myeloid leukemia (CML) sample representing several classes of chromosomal abnormalities. EGM showed 100% concordance with standard cytogenetic testing and OGM for clinically relevant structural and copy number variants, detecting all pathogenic abnormalities identified by standard-of-care testing as well as the corresponding findings observed with OGM.

Detected abnormalities included BCR::ABL1 rearrangements; whole-chromosome changes such as trisomy 4, trisomy 21, and monosomy 7; deletions; and complex structural variants. EGM also resolved smaller alterations, including a KMT2A partial tandem duplication. In one complex AML case, the platform further characterized a chromosome 20 abnormality as an intrachromosomal fusion, confirmed 20q loss, and identified an approximately 1.8 Mb deletion at 7q22.1 that had not been reported by karyotyping or FISH.

The findings are available as a preprint on medRxiv under the title “Electronic Genome Mapping Enables High-Resolution Cytogenomic Profiling of Hematologic Malignancies: A Proof-of-Principle Study.”

"Our laboratory has extensive experience evaluating genome mapping in hematologic malignancies, and we were interested in understanding how an electronic approach would perform in well-characterized specimens. In this initial five-sample proof-of-principle study, EGM detected all of the abnormalities identified by standard cytogenetic testing and OGM while also providing additional structural information in complex cases. These results support further evaluation of EGM in larger and more diverse cohorts," said Ravindra Kolhe, M.D., Ph.D., FCAP, Professor and Chair of the Department of Pathology at Augusta University.

Related Links
Augusta University
Nabsys
 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.